Re: Extension of Consulting Agreement with Orexigen Therapeutics, Inc. dated December 9, 2005
EXHIBIT 10.20
![(OREXIGEN LOGO)](https://www.sec.gov/Archives/edgar/data/1382911/000093639207000042/a25623a1a2562324.gif)
January 17, 2007
Xx. Xxxxxxx Xxxxxxx
President
PharmaDirections, Inc.
0000 Xxxxxx Xxxxxxx, Xxxxx 000
Xxxx , XX 00000
President
PharmaDirections, Inc.
0000 Xxxxxx Xxxxxxx, Xxxxx 000
Xxxx , XX 00000
Re:
|
Extension of Consulting Agreement with Orexigen | |
Therapeutics, Inc. dated December 9, 2005 |
Dear Xxxx:
We refer to the Consulting Agreement dated as of December 9, 2005 (the “Consulting Agreement”)
between Orexigen Therapeutics, Inc. and PharmaDirections, Inc. As you know, the Term of the
Consulting Agreement was set to expire on December 9, 2006. Notwithstanding the foregoing, both
parties have continued to work under the terms of the Consulting Agreement following this
expiration and as such desire to memorialize their mutual intent to extend the Term until December
31, 2007. Capitalized terms used herein and not otherwise defined herein shall have the meanings
set forth in the Consulting Agreement.
It is hereby agreed by you and us that:
(a) | Section 2 should be amended and replaced in its entirety to read as follows: | ||
“The term of this Agreement (the “Term”) shall commence on the date hereof and shall expire on December 31, 2007, unless extended by the mutual agreement of the Company and Consultant; provided that the Company may terminate the Agreement upon thirty (30) days written notice to Consultant. Sections 4, 5 and 6 shall survive expiration of the Term of termination of this Agreement.” | |||
(b) | The Consulting Agreement, as amended by this letter amendment, is and shall continue to be in full force and effect and is hereby in all respects ratified and confirmed. |
If you agree to the terms and provisions hereof, please evidence such agreement by executing and
returning a copy of the counterpart of this letter by pdf attachment to xxxxxxxxx@xxxxxxxx.xxx or
by facsimile to 000-000-0000, followed by one (1) counterpart of this letter amendment sent by mail
or courier to Orexigen Therapeutics, Inc., 00000 Xxxx Xxxxx Xxxxx, Xxxxx 000, Xxx Xxxxx, XX 00000,
Attention of Xxxxxxx XxXxxxxx. This letter amendment shall become effective as of the date first
above written when and if counterparts of this letter amendment shall have been executed by us and
you.
This letter amendment may be executed in any number of counterparts and by any combination of the
parties hereto in separate counterparts, each of which counterparts shall be an original and all of
which taken together shall constitute one and the same letter amendment, and this letter amendment
shall be governed by the laws of the State of North Carolina.
Very truly yours,
/s/
Xxxxxxx X. XxXxxxxx |
Xxxxxxx X. XxXxxxxx
Chief Operating Officer
Chief Operating Officer
APPROVED AND ACCEPTED THE 17th DAY OF JANUARY, 2007:
PharmaDirections, Inc.
|
||
By: |
/s/ Xx. Xxxxxxx Xxxxxxx |
|
Name: Xxxxxxx Xxxxxxx |
||
Title: President |
Orexigen Therapeutics Inc.
00000 Xxxx Xxxxx Xxxxx, Xxxxx 000, Xxx Xxxxx XX 00000
Office: 000-000-0000
Fax: 000-000-0000
xxx.xxxxxxxx.xxx
00000 Xxxx Xxxxx Xxxxx, Xxxxx 000, Xxx Xxxxx XX 00000
Office: 000-000-0000
Fax: 000-000-0000
xxx.xxxxxxxx.xxx